Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Darras

Showing results (251-260 of 303) with videos related to

Pageof 31
Sort By:
Muscle & Nerve|June 27, 2015
Old measures and new scores in spinal muscular atrophy patientsElena Mazzone, Jacqueline Montes, Marion Main, et al.
Muscle & Nerve|April 29, 2016
Rasch analysis of the Pediatric Evaluation of Disability Inventory-computer adaptive test (PEDI-CAT) item bank for children and young adults with spinal muscular atrophyAmy Pasternak, Georgios Sideridis, Maria Fragala-Pinkham, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 3, 2021
Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Plos One|April 9, 2013
SMA-MAP: a plasma protein panel for spinal muscular atrophyDione T Kobayashi, Jing Shi, Laurie Stephen, et al.
Neuromuscular Disorders : NMD|June 8, 2021
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersenGiorgia Coratti, Marika Pane, Simona Lucibello, et al.
Muscle & Nerve|October 5, 2016
Revised upper limb module for spinal muscular atrophy: Development of a new moduleElena S Mazzone, Anna Mayhew, Jacqueline Montes, et al.
Muscle & Nerve|July 25, 2014
Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophyAnne M Connolly, Elizabeth C Malkus, Jerry R Mendell, et al.
Neurology|August 1, 2014
Observational study of spinal muscular atrophy type I and implications for clinical trialsRichard S Finkel, Michael P McDermott, Petra Kaufmann, et al.
The Lancet. Neurology|March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.
Pageof 31

Showing results (251-260 of 303) with videos related to

Sort By:
Pageof 31
Muscle & Nerve|June 27, 2015
Old measures and new scores in spinal muscular atrophy patientsElena Mazzone, Jacqueline Montes, Marion Main, et al.
Muscle & Nerve|April 29, 2016
Rasch analysis of the Pediatric Evaluation of Disability Inventory-computer adaptive test (PEDI-CAT) item bank for children and young adults with spinal muscular atrophyAmy Pasternak, Georgios Sideridis, Maria Fragala-Pinkham, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 3, 2021
Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Plos One|April 9, 2013
SMA-MAP: a plasma protein panel for spinal muscular atrophyDione T Kobayashi, Jing Shi, Laurie Stephen, et al.
Neuromuscular Disorders : NMD|June 8, 2021
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersenGiorgia Coratti, Marika Pane, Simona Lucibello, et al.
Muscle & Nerve|October 5, 2016
Revised upper limb module for spinal muscular atrophy: Development of a new moduleElena S Mazzone, Anna Mayhew, Jacqueline Montes, et al.
Muscle & Nerve|July 25, 2014
Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophyAnne M Connolly, Elizabeth C Malkus, Jerry R Mendell, et al.
Neurology|August 1, 2014
Observational study of spinal muscular atrophy type I and implications for clinical trialsRichard S Finkel, Michael P McDermott, Petra Kaufmann, et al.
The Lancet. Neurology|March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.
Pageof 31